B. Braun Medical Launches Introcan Safety® 2 Deep Access IV Catheter

New longer-length IV catheter, designed to increase catheter dwell time, offers fully automatic, passive needlestick protection and multi-access blood control

BETHLEHEM, Pa., Oct. 1, 2026 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, today announced the launch of the Introcan Safety® 2 Deep Access IV Catheter, the newest addition to its ultrasound-guided deep access portfolio.

The new Introcan Safety 2 Deep Access IV Catheter combines clinically demonstrated extended-dwell performance¹ and multi-access blood control to help reduce blood exposure during repeated access. Designed for difficult venous access (DIVA) and extended therapy patients, it is engineered to help clinicians reach deeper vessels through a familiar insertion platform that can be readily integrated into existing workflows.

The peripheral IV catheter combines extended length, multi-access blood control and fully automatic passive safety protection. The blood control hub is designed to maintain blood control during insertion and every time the hub is accessed, helping minimize blood exposure and support a more efficient IV workflow. Passive safety technology is designed to reduce the risk of needlestick injuries without adding steps or workflow burden.

"The new Introcan Safety 2 Deep Access IV Catheter provides clinicians with another peripheral access option for difficult access and extended therapy patients," said Tyra Swavely, Group Product Director, Vascular Access. "Together with our new Peripheral Advantage®^plus Program, we're helping clinicians build confidence in ultrasound-guided access and appropriate device selection across a broader range of patient needs while continuing our focus on safety for patients and providers."

B. Braun will be exhibiting at Booth #103 at the AVA Scientific Meeting, October 2-4 in Grapevine, Texas. Attendees will be able to explore B. Braun's ultrasound-guided deep access portfolio, including the new Introcan Safety 2 Deep Access IV Catheter, Peripheral Advantage^plus Program and upcoming Introcan Safety Deep Access XL IV Catheter.

Peripheral Advantage^plus is B. Braun's newest vascular access program. It combines product technology and education designed to support clinician competency, appropriate device selection and advancement of vascular access care.

About B. Braun
B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we're uniquely positioned to help health systems succeed now and in the future. B. Braun is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap^® and CAPS^®. The company employs 8,500 people at over 30 locations across North America.

Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise^® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our website.

¹ Bahl A, Hijazi M, Chen NW, Clavette-Lachapelle L, Price J. Ultra long versus standard long peripheral intravenous catheters: a randomized controlled trial of ultrasound-guided catheter survival. 2019.

SOURCE B. Braun Medical Inc.